中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 151-156

Research advances in primary biliary cholangitis with dyslipidemia

DOI: 10.12449/JCH240125

  • Department of Gastroenterology，The Second Affiliated Hospital of Kunming Medical University，Kunming 650101，China

Research funding:

Medicine Leading Talents of Yunnan Province (L-2019013);

Yunnan Wanren Project (YNWR-MY-2018-028);

Clinical Research Project of the Second Affiliated Hospital of Kunming Medical University (2020ynlc010)

More Information
  • Corresponding author: TANG Yingmei， tangyingmei_med@kmmu.edu.cn （ORCID：0000-0002-0731-4198）
  • Received Date: 2023-05-04
  • Accepted Date: 2023-05-26
  • Published Date: 2024-01-23
    Abstract
  • Primary biliary cholangitis （PBC） is an autoimmune liver disease characterized by progressive and non-purulent inflammation of small- and medium-sized bile ducts in the liver. Recent studies have shown that abnormal lipid metabolism is relatively common in patients with PBC， and 76% of PBC patients have dyslipidemia. The effects and harms of dyslipidemia have attracted much attention. Lipid metabolism disorders play an important role in the progression of PBC. This article mainly reviews the research advances in the manifestation， role， diagnosis， and treatment of lipid metabolism disorders in PBC， so as to provide new ideas for the treatment of PBC.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    RESHETNYAK VI, MAEV IV. Features of lipid metabolism disorders in primary biliary cholangitis[J]. Biomedicines, 2022, 10( 12): 3046. DOI: 10.3390/biomedicines10123046.
    [2]
    ZENG N, DUAN WJ, CHEN S, et al. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: A systematic review and meta-analysis[J]. Hepatol Int, 2019, 13( 6): 788- 799. DOI: 10.1007/s12072-019-09984-x.
    [3]
    AHOUSSOUGBEMEY MELE A, MAHMOOD R, OGBUAGU H, et al. Hyperlipidemia in the setting of primary biliary cholangitis: A case report and review of management strategies[J]. Cureus, 2022, 14( 11): e31411. DOI: 10.7759/cureus.31411.
    [4]
    WAH-SUAREZ MI, DANFORD CJ, PATWARDHAN VR, et al. Hyperlipidaemia in primary biliary cholangitis: Treatment, safety and efficacy[J]. Frontline Gastroenterol, 2019, 10( 4): 401- 408. DOI: 10.1136/flgastro-2018-101124.
    [5]
    LOAEZA-DEL CASTILLO AM, GAYTÁN-SANTILLÁN A, LÓPEZ-TELLO A, et al. Patterns of serum lipids derangements and cardiovascular risk assessment in patients with primary biliary cholangitis[J]. Ann Hepatol, 2019, 18( 6): 879- 882. DOI: 10.1016/j.aohep.2019.07.006.
    [6]
    SEQUEIRA C, COELHO M, COSTA SANTOS I, et al. Severe Hypercholesterolemia mediated by lipoprotein X in an immunosuppressed patient: a case report[J]. GE Port J Gastroenterol, 2022, 30( 5): 398- 402. DOI: 10.1159/000526854.
    [7]
    FELLIN R, MANZATO E. Lipoprotein-X fifty years after its original discovery[J]. Nutr Metab Cardiovasc Dis, 2019, 29( 1): 4- 8. DOI: 10.1016/j.numecd.2018.09.006.
    [8]
    ZHANG Y, HU X, CHANG J, et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis[J]. BMC Gastroenterol, 2021, 21( 1): 395. DOI: 10.1186/s12876-021-01974-4.
    [9]
    KJELDSEN EW, NORDESTGAARD LT, FRIKKE-SCHMIDT R. HDL cholesterol and non-cardiovascular disease: A narrative review[J]. Int J Mol Sci, 2021, 22( 9): 4547. DOI: 10.3390/ijms22094547.
    [10]
    SARIN SK, KUMAR M, ESLAM M, et al. Liver diseases in the asia-pacific region: A lancet gastroenterology& hepatology commission[J]. Lancet Gastroenterol Hepatol, 2020, 5( 2): 167- 228. DOI: 10.1016/S2468-1253(19)30342-5.
    [11]
    LEMOINNE S, KEMGANG A, BELKACEM K BEN, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis[J]. Gut, 2020, 69( 1): 92- 102. DOI: 10.1136/gutjnl-2018-317791.
    [12]
    FELLIN R, MANZATO E. Lipoprotein-X fifty years after its original discovery[J]. Nutr Metab Cardiovasc Dis, 2019, 29( 1): 4- 8. DOI: 10.1016/j.numecd.2018.09.006.
    [13]
    NEMES K, ABERG F, GYLLING H, et al. Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications[J]. World J Hepatol, 2016, 8( 22): 924- 932. DOI: 10.4254/wjh.v8.i22.924.
    [14]
    HARRIS J, CAO S, HILE G, et al. Diffuse xanthomas in a patient with primary biliary cholangitis and lipoprotein X[J]. JAAD Case Rep, 2020, 7: 30- 32. DOI: 10.1016/j.jdcr.2020.10.029.
    [15]
    PAN XY, ZHANG ZM, LIU CQ, et al. Circulating levels of DDIT4 and mTOR, and contributions of BMI, inflammation and insulin sensitivity in hyperlipidemia[J]. Exp Ther Med, 2022, 24( 5): 666. DOI: 10.3892/etm.2022.11602.
    [16]
    MAHDAVI-ROSHAN M, SHOAIBINOBARIAN N, NOORMOHAMMADI M, et al. Inflammatory markers and atherogenic coefficient: Early markers of metabolic syndrome[J]. Int J Endocrinol Metab, 2022, 20( 4): e127445. DOI: 10.5812/ijem-127445.
    [17]
    SUN W, LI PC, CAI JP, et al. Lipid metabolism: Immune regulation and therapeutic prospectives in systemic lupus erythematosus[J]. Front Immunol, 2022, 13: 860586. DOI: 10.3389/fimmu.2022.860586.
    [18]
    SALAHUDDIN T, NATARAJAN B, PLAYFORD MP, et al. Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis[J]. Eur Heart J, 2015, 36( 39): 2662- 2665. DOI: 10.1093/eurheartj/ehv339.
    [19]
    WIDENMAIER SB, SNYDER NA, NGUYEN TB, et al. NRF1 is an ER membrane sensor that is central to cholesterol homeostasis[J]. Cell, 2017, 171( 5): 1094- 1109. e 15. DOI: 10.1016/j.cell.2017.10.003.
    [20]
    TALL AR, WESTERTERP M. Inflammasomes, neutrophil extracellular traps, and cholesterol[J]. J Lipid Res, 2019, 60( 4): 721- 727. DOI: 10.1194/jlr.S091280.
    [21]
    GILL PK, DRON JS, HEGELE RA. Genetics of hypertriglyceridemia and atherosclerosis[J]. Curr Opin Cardiol, 2021, 36( 3): 264- 271. DOI: 10.1097/HCO.0000000000000839.
    [22]
    ZHANG BH, YIN F, QIAO YN, et al. Triglyceride and triglyceride-rich lipoproteins in atherosclerosis[J]. Front Mol Biosci, 2022, 9: 909151. DOI: 10.3389/fmolb.2022.909151.
    [23]
    DEN HARTIGH LJ, ALTMAN R, NORMAN JE, et al. Postprandial VLDL lipolysis products increase monocyte adhesion and lipid droplet formation via activation of ERK2 and NFκB[J]. Am J Physiol Heart Circ Physiol, 2014, 306( 1): H109- H120. DOI: 10.1152/ajpheart.00137.2013.
    [24]
    LEE SH, KIM N, KIM M, et al. Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia[J]. Nat Commun, 2022, 13( 1): 5461. DOI: 10.1038/s41467-022-33202-2.
    [25]
    MANNE V, KOWDLEY KV. Obeticholic acid in primary biliary cholangitis: Where we stand[J]. Curr Opin Gastroenterol, 2019, 35( 3): 191- 196. DOI: 10.1097/MOG.0000000000000525.
    [26]
    LAZARIDIS KN, GORES GJ, LINDOR KD. Ursodeoxycholic acid‘mechanisms of action and clinical use in hepatobiliary disorders’[J]. J Hepatol, 2001, 35( 1): 134- 146. DOI: 10.1016/s0168-8278(01)00092-7.
    [27]
    NADINSKAIA M, MAEVSKAYA M, IVASHKIN V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2021, 27( 10): 959- 975. DOI: 10.3748/wjg.v27.i10.959.
    [28]
    MOUILLOT T, BEYLOT M, DRAI J, et al. Effect of bile acid supplementation on endogenous lipid synthesis in patients with short bowel syndrome: A pilot study[J]. Clin Nutr, 2020, 39( 3): 928- 934. DOI: 10.1016/j.clnu.2019.03.037.
    [29]
    HIRSCHFIELD GM, CHAZOUILLÈRES O, CORTEZ-PINTO H, et al. A consensus integrated care pathway for patients with primary biliary cholangitis: A guideline-based approach to clinical care of patients[J]. Expert Rev Gastroenterol Hepatol, 2021, 15( 8): 929- 939. DOI: 10.1080/17474124.2021.1945919.
    [30]
    PELLICCIARI R, FIORUCCI S, CAMAIONI E, et al. 6alpha-ethyl-chenodeoxycholic acid(6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity[J]. J Med Chem, 2002, 45( 17): 3569- 3572. DOI: 10.1021/jm025529g.
    [31]
    ROY PP, MAHTAB MA, RAHIM MA, et al. Treatment of nonalcoholic steatohepatitis by obeticholic acid: Current status[J]. Euroasian J Hepatogastroenterol, 2022, 12( Suppl 1): S46- S50. DOI: 10.5005/jp-journals-10018-1360.
    [32]
    NEVENS F, ANDREONE P, MAZZELLA G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J]. N Engl J Med, 2016, 375( 7): 631- 643. DOI: 10.1056/NEJMoa1509840.
    [33]
    SAMUR S, KLEBANOFF M, BANKEN R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J]. Hepatology, 2017, 65( 3): 920- 928. DOI: 10.1002/hep.28932.
    [34]
    KURIHARA T, AKIMOTO M, ABE K, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia[J]. Clin Ther, 1993, 15( 5): 890- 898.
    [35]
    GU Y, YANG XQ, LIANG H, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2019, 19( 1): 231. DOI: 10.1186/s12876-019-1147-1.
    [36]
    SPELIOTES EK, BALAKRISHNAN M, FRIEDMAN LS, et al. Treatment of dyslipidemia in common liver diseases[J]. Clin Gastroenterol Hepatol, 2018, 16( 8): 1189- 1196. DOI: 10.1016/j.cgh.2018.04.023.
    [37]
    YAMAGUCHI M, ASANO T, ARISAKA T, et al. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia[J]. Hepatol Res, 2022, 52( 6): 522- 531. DOI: 10.1111/hepr.13747.
    [38]
    DING DW, GUO GY, LIU YS, et al. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid[J]. Hepatol Commun, 2022, 6( 12): 3487- 3495. DOI: 10.1002/hep4.2103.
    [39]
    SHAPIRO MD, TAVORI H, FAZIO S. PCSK9: From basic science discoveries to clinical trials[J]. Circ Res, 2018, 122( 10): 1420- 1438. DOI: 10.1161/CIRCRESAHA.118.311227.
    [40]
    NISSEN SE, STROES E, DENT-ACOSTA RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial[J]. JAMA, 2016, 315( 15): 1580- 1590. DOI: 10.1001/jama.2016.3608.
    [41]
    HUR KY, MOON MK, PARK JS, et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean diabetes association[J]. Diabetes Metab J, 2021, 45( 4): 461- 481. DOI: 10.4093/dmj.2021.0156.
    [42]
    GRUNDY SM, STONE NJ, BAILEY AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Circulation. 2019, 139( 25): e1082- e1143. DOI: 10.1161/CIR.0000000000000625.
    [43]
    MACH F, BAIGENT C, CATAPANO AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41( 1): 111- 188. DOI: 10.1093/eurheartj/ehz455.
    [44]
    TUMMALA R, GUPTA M, DEVANABANDA AR, et al. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis[J]. Ann Med, 2022, 54( 1): 1287- 1296. DOI: 10.1080/07853890.2022.2059559.
    [45]
    AGHA AM, JONES PH, BALLANTYNE CM, et al. Greater than expected reduction in low-density lipoprotein-cholesterol(LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia(HeFH)[J]. J Clin Lipidol, 2021, 15( 5): 649- 652. DOI: 10.1016/j.jacl.2021.07.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (324) PDF downloads(60) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return